Biologic and small molecule therapies for psoriasis in individuals with Down syndrome: Two cases and a systematic review
Down syndrome (DS), also known as trisomy 21, is a genetic condition linked to a higher prevalence of skin disorders, including psoriasis, which affects up to 8% of individuals. DS patients with psoriasis present unique management considerations, including a theoretical increased risk of infectious...
Saved in:
| Main Authors: | Michal Moshkovich, Jonah W. Perlmutter, Ronald Vender |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2025-07-01
|
| Series: | SAGE Open Medical Case Reports |
| Online Access: | https://doi.org/10.1177/2050313X251359029 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Biologicals and small molecules in psoriasis: A systematic review of economic evaluations.
by: Christian Kromer, et al.
Published: (2018-01-01) -
Two cases of severe childhood-onset psoriasis successfully treated with risankizumab in patients with Down syndrome and morbid obesity
by: Yoshiaki Hara, et al.
Published: (2025-08-01) -
SAFETY OF BIOLOGICAL PREPARATIONS AND SMALL MOLECULES. ARE THERE ANY DIFFERENCES?
by: A. S. Kolbin, et al.
Published: (2013-05-01) -
Acrodermatitis continua of Hallopeau: a review and update on biological and small molecule targeted immunomodulatory therapies
by: Qiong Sun, et al.
Published: (2025-08-01) -
The Use of Tissue Concentrations of Biological and Small-Molecule Therapies in Clinical Studies of Inflammatory Bowel Diseases
by: Ahmed B. Bayoumy, et al.
Published: (2024-11-01)